業績集 -Publications-

欧文雑誌

• Higasihara T, Odawara M, Sugasawa T, Suzuki Y, Kametaka S, Inagi R, Nangaku M, Nishi H. Uremia Impedes Skeletal Myocyte Myomixer Expression and Fusogenic Activity: Implication for Uremic Sarcopenia.
  American Journal of Pathology “in press"
• Kawabata C, Hirakawa Y, Inagi R, Nangaku M. Acetate attenuates kidney fibrosis in an oxidative stress-dependent manner.
  Physiol Rep. 2023 Jul;11(14):e15774. doi: 10.14814/phy2.15774.
• Nakamura Y, Matsumoto H, Wu CH, Fukaya D, Uni R, Hirakawa Y, Katagiri M, Yamada S, Ko T, Nomura S, Wada Y, Komuro I, Nangaku M, Inagi R, Inoue T. Alpha 7 nicotinic acetylcholinereceptors signaling boosts cell-cell interactions in macrophages effecting anti-inflammatory and organ protection.
  Commun Biol. 2023 Jun 23;6(1):666. doi: 10.1038/s42003-023-05051-2.
• Bravo-Sagua R, Lopez-Crisosto C, Criollo A, Inagi R, Lavandero S. Organelle Communication: Joined in Sickness and in Health.
  Physiology (Bethesda). 2023 May 1;38(3):0. doi: 10.1152/physiol.00024.2022.
• Nangaku M, Kitching AR, Boor P, Fornoni A, Floege J, Coates PT, Himmelfarb J, Lennon R, Anders HJ, Humphreys BD,
  Caskey FJ, Fogo AB; TRANSFORM group.
  International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology.
  Kidney Int. 2023 Mar 28:S0085-2538(23)00174-6. doi: 10.1016/j.kint.2023.03.007.
• Inagi R, Yoshioka K. Stray tubules: the varied and dynamic fate of tubular cells.
  Kidney Int. 2023 Feb 18:S0085-2538(23)00088-1. doi: 10.1016/j.kint.2023.02.005.
• Hasegawa S, Inagi R. Molecular mechanisms of kidney crosstalk with distant organs.
  Nat Rev Nephrol. 2023 Feb;19(2):75-76. doi: 10.1038/s41581-022-00655-z.
• Inagi R, Hasegawa S. Good and evil, more reasons to study UPR.
  Kidney Int. 2023 Feb;103(2):254-256. doi: 10.1016/j.kint.2022.09.015.
• Inoue T, Nakamura Y, Tanaka S, Kohro T, Li LX, Huang L, Yao J, Kawamura S, Inoue R, Nishi H, Fukaya D, Uni R, Hasegawa S, Inagi R, Umene R, Wu CH, Ye H, Bajwa A, Rosin DL, Ishihara K, Nangaku M, Wada Y, Okusa MD. Bone marrow stromal cell antigen-1 (CD157) regulated by sphingosine kinase 2 mediates kidney fibrosis.
  Front Med (Lausanne). 2022 Oct 4;9:993698. doi: 10.3389/fmed.2022.993698.
• Hirakawa Y, Yoshioka K, Kojima K, Yamashita Y, Shibahara T, Wada T, Nangaku M, Inagi R. Potential progression biomarkers of diabetic kidney disease determined using comprehensive machine learning analysis of non-targeted metabolomics.
  Sci Rep. 2022 Sep 29;12(1):16287. doi: 10.1038/s41598-022-20638-1.
• Okpechi IG, Caskey FJ, Gaipov A, Tannor EK, Noubiap JJ, Effa E, Ekrikpo UE, Hamonic LN, Ashuntantang G, Bello AK, Donner JA, Figueiredo AE, Inagi R, Madero M, Malik C, Moorthy M, Pecoits-Filho R, Tesar V, Levin A, Jha V. Early Identification of CKD-A Scoping Review of the Global Populations.
  Kidney Int Rep. 2022 Apr 6;7(6):1341-1353. doi: 10.1016/j.ekir.2022.03.031.
• Inagi R. Organelle Stress and Metabolic Derangement in Kidney Disease.
  Int J Mol Sci. 2022 Feb 2;23(3):1723. doi: 10.3390/ijms23031723.
• Wu CH, Inoue T, Nakamura Y, Uni R, Hasegawa S, Maekawa H, Sugahara M, Wada Y, Tanaka T, Nangaku M, Inagi R. Activation of α7 nicotinic acetylcholine receptors attenuates monocyte-endothelial adhesion through FUT7 inhibition.
  Biochem Biophys Res Commun. 2022 Jan 29;590:89-96. doi: 10.1016/j.bbrc.2021.12.094.
• Yoshioka K, Hirakawa Y, Kurano M, Ube Y, Ono Y, Kojima K, Iwama T, Kano K, Hasegawa S, Inoue T, Shimada T, Aoki J, Yatomi Y, Nangaku M, Inagi R. Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease.
  Kidney Int. 2022 Mar;101(3):510-526. doi: 10.1016/j.kint.2021.10.039.
• Okpechi IG, Caskey FJ, Gaipov A, Tannor EK, Hamonic LN, Ashuntantang G, Donner JA, Figueiredo A, Inagi R, Madero M, Malik C, Moorthy M, Pecoits-Filho R, Tesar V, Levin A, Jha V. Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review.
  BMJ Open. 2021 Dec 16;11(12):e053857. doi: 10.1136/bmjopen-2021-053857.
• Hasegawa S, Inagi R. The subtle long-lasting burden of mitochondrial DNA variants.
  Nat Rev Nephrol. 2021 Oct 18. doi: 10.1038/s41581-021-00500-9.
• Sakashita M, Tanaka T, Inagi R. Metabolic Changes and Oxidative Stress in Diabetic Kidney Disease.
  Antioxidants (Basel). 2021 Jul 19;10(7):1143. doi: 10.3390/antiox10071143.
• Fujii R, Hasegawa S, Maekawa H, Inoue T, Yoshioka K, Uni R, Ikeda Y, Nangaku M, Inagi R. Decreased IFT88 expression with primary cilia shortening causes mitochondrial dysfunction in cisplatin-induced tubular injury.
  Am J Physiol Renal Physiol. 2021 Sep 1;321(3):F278-F292. doi: 10.1152/ajprenal.00673.2020.
• Doi K, Kimura H, Wada T, Tanaka T, Hiromura K, Saleem MA, Inagi R, Nangaku M, Fujii T. A novel method for successful induction of interdigitating process formation in conditionally immortalized podocytes from mice, rats, and humans.
  Biochem Biophys Res Commun. 2021 Sep 17;570:47-52. doi: 10.1016/j.bbrc.2021.07.029.
• Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y. Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function.
  Ther Apher Dial. 2021 May 31. doi: 10.1111/1744-9987.13694.
• Hasegawa S, Inagi R. Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease.
  Curr Diab Rep. 2021 May 11;21(7):21. doi: 10.1007/s11892-021-01390-8.
• Higashihara T, Nishi H, Takemura K, Watanabe H, Maruyama T, Inagi R, Tanaka T, Nangaku M. β2-adrenergic receptor agonist counteracts skeletal muscle atrophy and oxidative stress in uremic mice.
  Sci Rep. 2021 Apr 28;11(1):9130. doi:10.1038/s41598-021-88438-7.
• Hasegawa S, Inoue T, Nakamura Y, Fukaya D, Uni R, Wu CH, Fujii R, Peerapanyasut W, Taguchi A, Kohro T, Yamada S, Katagiri M, Ko T, Nomura S, Nakanishi Ozeki A, Susaki EA, Ueda HR, Akimitsu N, Wada Y, Komuro I, Nangaku M, Inagi R. Activation of Sympathetic Signaling in Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-Reperfusion Injury.
  J Am Soc Nephrol. 2021 Apr 19:ASN.2020121723. doi: 10.1681/ASN.2020121723.
• Inagi R. Organelle stress and glycation in kidney disease.
  Glycoconj J. 2021 Jun;38(3):341-346. doi: 10.1007/s10719-021-09989-5.
• Ouchi H, Hirakawa Y, Inagi R. D-serine as a Novel Uremic Toxin.
  In book: Uremic Toxins and Organ Failure (pp.115-129) 2020 Oct. doi: 10.1007/978-981-15-7793-2_8
• Hasegawa S, Inagi R. Organelle Stress and Crosstalk in Kidney Disease.
  Kidney360 2020 Oct;1 (10) 1157-1164. doi: https://doi.org/10.34067/KID.0002442020
• Takemura K, Nishi H, Inagi R. Mitochondrial Dysfunction in Kidney Disease and Uremic Sarcopenia.
  Front Physiol. 2020 Sep 4;11:565023. doi: 10.3389/fphys.2020.565023.
• Inagi R. The Implication of Organelle Cross Talk in AKI.
  Nephron. 2020;144(12):634-637. doi: 10.1159/000508639.
• Chikamori M, Kimura H, Inagi R, Zhou J, Nangaku M, Fujii T. Intracellular calcium response of primary cilia of tubular cells to modulated shear stress under oxidative stress.
  Biomicrofluidics. 2020 Jul 2;14(4):044102. doi: 10.1063/5.0010737.
• Uni R, Abe C, Inagi R Inoue T. Role of the Nervous System in Acute Kidney Injury.
  In book: Acute Kidney Injury and Regenerative Medicine (pp.297-316) 2020 May. doi: 10.1007/978-981-15-1108-0_21
• Nishi H, Takemura K, Higashihara T, Inagi R. Uremic Sarcopenia: Clinical Evidence and Basic Experimental Approach.
  Nutrients. 2020 Jun 18;12(6):E1814. doi: 10.3390/nu12061814.
• Uni R, Inoue T, Nakamura Y, Fukaya D, Hasegawa S, Wu CH, Fujii R, Surattichaiyakul B, Peerapanyasut W, Ozeki A, Akimitsu N, Wada Y, Nangaku M, Inagi R. Vagus nerve stimulation even after injury ameliorates cisplatin-induced nephropathy via reducing macrophage infiltration.
  Sci Rep. 2020 Jun 11;10(1):9472. doi: 10.1038/s41598-020-66295-0.
• Sugahara M, Tanaka S, Tanaka T, Saito H, Ishimoto Y, Wakashima T, Ueda M, Fukui K, Shimizu A, Inagi R, Yamauchi T, Kadowaki T, Nangaku M. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
  J Am Soc Nephrol. 2020 Mar;31(3):560-577. doi: 10.1681/ASN.2019060582.
• Maekawa H, Inagi R. Pathophysiological Role of Organelle Stress/Crosstalk in AKI-to-CKD Transition.
  Semin Nephrol. 2019 Nov;39(6):581-588. doi: 10.1016/j.semnephrol.2019.10.007.
• Maekawa H, Inoue T, Ouchi H, Jao TM, Inoue R, Nishi H, Fujii R, Ishidate F, Tanaka T, Tanaka Y, Hirokawa N, Nangaku M, Inagi R. Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury.
  Cell Rep. 2019 Oct 29;29(5):1261-1273.e6. doi: 10.1016/j.celrep.2019.09.050.
• Hasegawa S, Inoue T, Inagi R. Neuroimmune interactions and kidney disease.
  Kidney Res Clin Pract. 2019 Sep 30;38(3):282-294. doi: 10.23876/j.krcp.19.014. Review.
• Nishi H, Higashihara T, Inagi R. Lipotoxicity in Kidney, Heart, and Skeletal Muscle Dysfunction.
  Nutrients. 2019 Jul 20;11(7). pii: E1664. doi: 10.3390/nu11071664. Review.
• Ducasa GM, Mitrofanova A, Mallela SK, Liu X, Molina J, Sloan A, Pedigo CE, Ge M, Santos JV, Hernandez Y, Kim JJ, Maugeais C, Mendez AJ, Nair V, Kretzler M, Burke GW, Nelson RG, Ishimoto Y, Inagi R, Banerjee S, Liu S, Szeto HH, Merscher S, Fontanesi F, Fornoni A. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes.
  J Clin Invest. 2019 Jul 22;129(8):3387-3400. doi: 10.1172/JCI125316. eCollection 2019 Jul 22.
• Mitrofanova A, Mallela SK, Ducasa GM, Yoo TH, Rosenfeld-Gur E, Zelnik ID, Molina J, Varona Santos J, Ge M, Sloan A, Kim JJ, Pedigo C, Bryn J, Volosenco I, Faul C, Zeidan YH, Garcia Hernandez C, Mendez AJ, Leibiger I, Burke GW, Futerman AH, Barisoni L, Ishimoto Y, Inagi R, Merscher S, Fornoni A. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease.
  Nat Commun. 2019 Jun 19;10(1):2692. doi: 10.1038/s41467-019-10584-4.
• Tatsuzaki J, Ohwada T, Otani Y, Inagi R, Ishikawa T. A simple and effective preparation of quercetin pentamethyl ether from quercetin.
  Beilstein J Org Chem. 2018 Dec 28;14:3112-3121. doi: 10.3762/bjoc.14.291. eCollection 2018.
• Inoue T, Maekawa H, Inagi R. Organelle crosstalk in the kidney.
  Kidney Int. 2019 2019 Jun;95(6):1318-1325. doi: 10.1016/j.kint.2018.11.035. Epub 2019 Mar 4. Review.
• Jao TM, Nangaku M, Wu CH, Sugawara M, Saito H, Maekawa H, Ishimoto Y, Aoe M, Inoue T, Tanaka T, Staels B, Mori K, Inagi R. ATF6α and PPARα crosstalk provides new insights into lipotoxicity-induced tubulointerstitial fibrosis.
  Kidney Int. 2018 2019 Mar;95(3):577-589. doi: 10.1016/j.kint.2018.09.023. Epub 2019 Jan 11.
• Inoue T, Abe C, Kohro T, Tanaka S, Huang L, Yao J, Zheng S, Ye H, Inagi R, Stornetta RL, Rosin DL, Nangaku M, Wada Y, Okusa MD. Non-canonical cholinergic anti-inflammatory pathway-mediated activation of peritoneal macrophages induces Hes1 and blocks kidney injury.
  Kidney Int. 2018 2019 Mar;95(3):563-576. doi: 10.1016/j.kint.2018.09.020. Epub 2019 Jan 19.
• Inoue T, Tanaka S, Rosin DL, Okusa MD. Bioelectronic Approaches to Control Neuroimmune Interactions in Acute Kidney Injury.
  Cold Spring Harb Perspect Med. 2018 Aug 20. pii: a034231. doi: 10.1101/cshperspect.a034231. [Epub ahead of print]
• Ishimoto Y, Tanaka T, Yoshida Y, Inagi R. Physiological and Pathophysiological Role of Reactive Oxygen Species and Reactive Nitrogen Species in the Kidney.
  Clin Exp Pharmacol Physiol. 2018 Jul 27. doi: 10.1111/1440-1681.13018. [Epub ahead of print] Review.
• Tanaka S, Sugiura Y, Saito H, Sugahara M, Higashijima Y, Yamaguchi J, Inagi R, Suematsu M, Nangaku M, Tanaka T. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
  Kidney Int. 2018 Jul 13. pii: S0085-2538(18)30353-3. doi: 10.1016/j.kint.2018.04.025. [Epub ahead of print]
• Anusornvongchai T, Nagaku M, Jao TM, Wu CH, Ishimoto Y, Maekawa H, Tanaka T, Shimizu A, Yamanoto M, Suzuki N, Sassa R, Inagi R. Palmitate deranges erythropoietin production via ATF4 activation of unfolded protein response.
  Kidney Int. 2018 Jun 7. pii: S0085-2538(18)30250-3. doi: 10.1016/j.kint.2018.03.011. [Epub ahead of print]
• Lin CC, Kurashige M, Liu Y, Terabayashi T, Ishimoto Y, Wang T, Choudhary V, Hobbs R, Liu LK, Lee PH, Outeda P, Zhou F, Restifo NP, Watnick T, Kawano H, Horie S, Prinz W, Xu H, Menezes LF, Germino GG. A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed.
  Sci Rep. 2018 Feb 9;8(1):2743. doi: 10.1038/s41598-018-20856-6.
• Ishimoto Y, Inagi R, Yoshihara D, Kugita M, Nagao S, Shimizu A, Takeda N, Wake M, Honda K, Zhou J, Nangaku M. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
  Mol Cell Biol. 2017 Oct 9. pii: MCB.00337-17. doi: 10.1128/MCB.00337-17. [Epub ahead of print] PubMed PMID: 28993480.
• Inagi R, Ishimoto Y, Jao TM. Foreseeing the future of glomerular disease through slits: miR-NPNT axis.
  Kidney Int. 2017 Oct;92(4):782-784. doi:10.1016/j.kint.2017.04.036.
• Okada A, Nangaku M, Jao TM, Maekawa H, Ishimono Y, Kawakami T, Inagi R. D-serine, a novel uremic toxin, induces senescence in human renal tubular cells via GCN2 activation.
  Sci Rep. 2017 Sep 11;7(1):11168. doi:10.1038/s41598-017-11049-8. PubMed PMID: 28894140; PubMed Central PMCID:PMC5593843.
• Sasaki M, Sasako T, Kubota N, Sakurai Y, Takamoto I, Kubota T, Inagi R, Seki G, Goto M, Ueki K, Nangaku M, Jomori T, Kadowaki T. Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney.
  Diabetes. 2017 Sep;66(9):2339-2350. doi: 10.2337/db16-1602.
• Nangaku M, Hirakawa Y, Mimura I, Inagi R, Tanaka T. Epigenetic Changes in the Acute Kidney Injury-to-Chronic Kidney Disease Transition.
  Nephron. 2017 Jun 9. doi: 10.1159/000476078. [Epub ahead of print]
• Hirakawa Y, Jao TM, Inagi R. Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress.
  Clin Exp Pharmacol Physiol. 2017 May 3. doi: 10.1111/1440-1681.12777. [Epub ahead of print]
• Hasegawa S, Jao TM, Inagi R. Dietary Metabolites and Chronic Kidney Disease.
  Nutrients. 2017 Apr 4;9(4). pii: E358. doi: 10.3390/nu9040358. Review.
• Tanaka S, Tanaka T, Kawakami T, Takano H, Sugahara M, Saito H, Higashijima Y, Yamaguchi J, Inagi R, Nangaku M. Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury.
  Kidney Int. 2017 Jul;92(1):154-164. doi: 10.1016/j.kint.2017.01.014.
• Maekawa H, Inagi R. Stress Signal Network between Hypoxia and ER Stress in Chronic Kidney Disease.
  Front Physiol. 2017 Feb 8;8:74.
• Hirakawa Y, Inagi R. Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.
  Int J Mol Sci. 2017 Jan 17;18(1). pii: E174.
• Yamaguchi J, Tanaka T, Inagi R. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy.
  Nephron. 2017;135(3):201-206.
• Inagi R. RAGE and glyoxalase in kidney disease.
  Glycoconj J. 2016 Aug;33(4):619-26.
• Nakatani Y, Inagi R. Epigenetic Regulation Through SIRT1 in Podocytes.
  Curr Hypertens Rev. 2016;12(2):89-94.
• Ishimoto Y, Inagi R. Mitochondria: a therapeutic target in acute kidney injury.
  Nephrol Dial Transplant. 2016 Jul;31(7):1062-9.
• Inagi R. The gut-kidney connection in advanced chronic kidney disease.
  Kidney Res Clin Pract. 2015 Dec;34(4):191-3.
• Persson P, Friederich-Persson M, Fasching A, Hansell P, Inagi R, Palm F. Adenosine A2 a receptor stimulation prevents proteinuria in diabetic rats by promoting an anti-inflammatory phenotype without affecting oxidative stress.
  Acta Physiol (Oxf). 2015 Jul;214(3):311-8.
• Nangaku M, Inagi R, Mimura I, Tanaka T. Epigenetic Changes Induced by Hypoxia-Inducible Factor: a Long Way Still To Go as a Target for Therapy？
  J Am Soc Nephrol. 2015 Jul;26(7):1478-80.
• Motonishi S, Nangaku M, Wada T, Ishimoto Y,Ohse T, Matsusaka T, Kubota N, Shimizu A, Kadowaki T, Tobe K, Inagi R. Sirtuin1 maintains actin cytoskeleton by deacetylation of cortactin in injured podocytes.
  J Am Soc Nephrol. 2015 Aug;26(8):1939-59.
• Nordquist L, Friederich-Persson M, Fasching A, Liss P, Shoji K, Nangaku M,Hansell P, Palm F. Activation of Hypoxia-Inducible Factors Prevents Diabetic Nephropathy.
  J Am Soc Nephrol. 2015 Feb;26(2):328-38.
• Kawakami T, Mimura I, Shoji K, Tanaka T, Nangaku M. Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes.
  Kidney Int Suppl (2011). 2014 Nov;4(1):107-112. Review.
• Inagi R, Ishimoto Y, Nangaku M. Proteostasis in endoplasmic reticulum-new mechanisms in kidney disease.
  Nat Rev Nephrol. 2014 Jul;10(7):369-78.
• Inagi R. Glycative stress and glyoxalase in kidney disease and aging.
  Biochem Soc Trans. 2014 Apr;42(2):457-60.
• Shoji K, Tanaka T, Nangaku M. Role of hypoxia in progressive chronic kidney disease and implications for therapy.
  Curr Opin Nephrol Hypertens. 2014 Mar;23(2):161-8.
• Jo-Watanabe A, Ohse T, Nishimatsu H, Takahashi M, Ikeda Y, Wada T, Shirakawa J,Nagai R, Miyata T, Nagano T, Hirata Y, Inagi R, Nangaku M. Glyoxalase I reduces glycative and oxidative stress and prevents age-related endothelial dysfunction through modulation of endothelial nitric oxide synthase phosphorylation.
  Aging Cell. 2014 Jun;13(3):519-28.
• Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto K, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
  Kidney Int. 2014 Mar;85(3):641-8.
• Shoji K, Murayama T, Mimura I, Wada T, Kume H, Goto A, Ohse T, Tanaka T, Inagi R, van der Hoorn FA, Manabe I, Homma Y, Fukayama M, Sakurai T, Hasegawa T, Aburatani H, Kodama T, Nangaku M. Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma.
  Am J Pathol. 2013 Jun;182(6):2191-203.
• Chiang CK, Nangaku M, Tanaka T, Iwawaki T, Inagi R. Endoplasmic reticulum stress signal impairs erythropoietin production: a role for ATF4.
  Am J Physiol Cell Physiol.2013 Feb 15;304(4):C342-53.

国内原著

• 岡田啓,　稲城玲子. 　腎臓を中心とした小胞体ストレスと臓器間ネットワーク.　最新醫學.
  最新医学社　2017;72:752-772.
• 前川洋,　稲城玲子. 　小胞体ストレス、UPR経路は慢性腎臓病の創薬ターゲットである.　尿酸と血糖.
  先端医学社　2017;3:175-179.
• 正路久美,　稲城玲子. 　飽和脂肪酸の生物学.　腎臓内科・泌尿器科.
  科学評論社　2016;4:521-528.
• 前川洋,　稲城玲子. 　腸内細菌と慢性腎臓病.　Medical Practice.
  文光堂　2016;33:893-897.
• 前川洋,　稲城玲子. 　酸化ストレスの糖尿病合併症に対する影響―糖尿病性腎症を中心にー.　腎と透析.
  東京医学社 　2016;81:991-996.
• 城愛理,　稲城玲子.　疾患とメイラード反応.　メイラード反応の機構・制御・利用.
  シーエムシー出版　2016; pp39-47.
• 前川洋,　稲城玲子.　腸内細菌叢の腎臓に及ぼす影響.　腎臓内科・泌尿器科.
  科学評論社　2015;2:488-498.
• 本西秀太,　稲城玲子.　ポドサイトにおけるSIRT1の新たな役割.＜公募研究助成報告書＞　日本透析医会雑誌.
  日本透析医会　2015;30:306-312.
• 平川陽亮,　稲城玲子.　糖化ストレスとアンチエイジング.　腎臓内科・泌尿器科.
  科学評論社　2015;2:107-114.
• 岡田啓,　稲城玲子.　AGEによる腎障害と老化.　細胞.
  ニューサイエンス社　2015;47:470-474.
• 平川陽亮,　稲城玲子.　小胞体ストレスとProteostasis.　Annual Review 腎臓2015.
  中外医学社　2015; pp19-25.
• 本西秀太,　稲城玲子.　ポドサイトとストレス応答.　 腎と透析.
  東京医学社 2015;78:395-399.
• 平川陽亮,　稲城玲子.　メタボロミクス.　腎臓内科・泌尿器科.
  科学評論社　2015;1:304-310.
• 石本　遊,　稲城玲子.　慢性腎臓病における低酸素・小胞体ストレス応答の分子機序.　Annual Review 腎臓2014.
  中外医学社　2014; pp97-104.
• 平川陽亮,　稲城玲子,　南学正臣.　腎性貧血と腎機能低下：New findings in a moving filed. 腎と透析【保存期腎性貧血の病態と治療-温故知新-】.
  東京医学社 2014;76:247-251.
• 平川陽亮,　稲城玲子.　Proteostasisと腎臓病.　医学の歩み　腎臓病のすべて.
  医歯薬出版株式会社　2014; pp970-974.
• 稲城玲子.　小胞体ストレスによるEPO産生制御. 全人力・科学力・透析力に基づく透析医学.
  医薬ジャーナル社　2014; pp355-358.
• 城愛理,　稲城玲子,　南学正臣.　AGEsと糖尿病性腎症.　AGEｓと老化—糖化制御からみたウェルエイジングー.
  メディカルレビュー社　2013; pp125-133.
• 稲城玲子　【総括】　小胞体ストレスと闘う身体—小胞体が発信する生体適応シグナルと生活習慣病—　細胞　特集：小胞体ストレス.
  ニューサイエンス社　2013;45:164-167.
• 稲城玲子,　南学正臣.　新しい腎性貧血治療法.　腎と透析【腎性貧血-概念の進歩と治療への期待】.
  東京医学社　2013;75:417-421.
• 正路久美,　稲城玲子, 南学正臣.　腎性貧血.　腎臓　大規模臨床試験の結果　日常診療へのインパクト.
  日本腎臓財団　2013;36:152-159.
• 稲城玲子.　転写調節因子Nrf2活性化による腎機能改善治療.　Medical Practice　【CKD(慢性腎臓病)ガイドラインに基づく有効なこれからの実地診療】.
  文光堂　2013; pp1968-1973.
• 城 愛理, 南学 正臣, 稲城 玲子. 糖化ストレスを抑制して血管を若く保つ. 基礎老化研究.
  日本基礎老化学会　2013;37:33-35.